Volume | 13,255 |
|
|||||
News | - | ||||||
Day High | 0.0007 | Low High |
|||||
Day Low | 0.0007 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Statera BioPharma Inc (CE) | STAB | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.0007 | 0.0007 | 0.0007 | 0.0007 | 0.0007 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
4 | 13,255 | US$ 0.0007 | US$ 9 | - | 0.000001 - 0.038 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
11:53:50 | 5 | US$ 0.0007 | USD |
Statera BioPharma Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 50.81k | 72.58M | 53.10M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Statera BioPharma (CE) News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STAB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 1,061 | 0.00 | 0.00% |
1 Month | 0.0006 | 0.0007 | 0.0006 | 0.0006663 | 5,471 | 0.0001 | 16.67% |
3 Months | 0.0006 | 0.0007 | 0.0003 | 0.0006042 | 29,643 | 0.0001 | 16.67% |
6 Months | 0.000001 | 0.0103 | 0.000001 | 0.0005229 | 26,202 | 0.0007 | 69,900.00% |
1 Year | 0.0205 | 0.038 | 0.000001 | 0.0167877 | 48,152 | -0.0198 | -96.59% |
3 Years | 0.0676 | 0.08 | 0.000001 | 0.0274226 | 217,072 | -0.0669 | -98.96% |
5 Years | 0.0676 | 0.08 | 0.000001 | 0.0274226 | 217,072 | -0.0669 | -98.96% |
Statera BioPharma (CE) Description
Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis. To learn more about Statera Biopharma, please visit www.staterabiopharma.com. |